Travel is back and in a big way. According to a new U.S. Travel Association report, for the first time since the start of the pandemic, travel spending ($100
Travel is back and in a big way. According to a new U.S. Travel Association report, for the first time since the start of the pandemic, travel spending ($100 billion) was 3% above 2019 levels in April 2022 and more than one-quarter (28%) of travelers plan to spend significantly more this summer over their 2019Travel is back and in a big way. According to a new U.S. Travel Association report, for the first time since the start of the pandemic, travel spending ($100 billion) was 3% above 2019 levels in April 2022 and more than one-quarter (28%) of travelers plan to spend significantly more this summer over their 2019 ยป The FINANCIAL Travel Biz
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections For media and investors
Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ViiV
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV preventionGiven as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of H.